Raloxifene would not act like estrogen in the uterus and is not connected to a heightened hazard of uterine most cancers.Focusing on tissue architecture via Rho GTPase inhibition with smaller molecules is surely an rising spot for possible therapeutic intervention in most cancers. It could modulate tissue stiffness, cellular rheology, vasodilation